LUNG DRUG DELIVERY WITH CARBON DIOXIDE AEROSOL INHALERS

描述(改编自《调查者摘要》)：氯氟烃 (氯氟化碳)推进剂目前用于肺疾病的计量吸入器 由于其高臭氧消耗潜力，药物输送正在被逐步淘汰。 一个国际制药业财团提议， 零臭氧消耗潜能氢氟烷(HFA)推进剂将取代 计量吸入器中的氟氯化碳。然而，仍然有关键的原因需要找到 其他药物雾化替代品。HFA的潜在问题 推进剂包括毒性、与设备的不相容、不相容 使用FDA批准的吸入器表面活性剂和一些降低的生物利用度 毒品。研究人员已经为一种肺气雾剂的方法申请了专利 以超临界流体二氧化碳为载体的药物输送 吸入剂推进剂，并已在体内证明了其潜在的用途 几项实验室研究。调查人员已经设计了一些吸入器 使用二氧化碳作为推进剂的原型，并正在寻求资金 这些设备的额外研究和开发。这项技术已经 几个优点包括零臭氧消耗潜能推进剂，低 二氧化碳的毒性，以及对肺部的管理能力 目前不能通过任何其他方法提供的亲脂性药物。这个 研究人员建议改进并彻底测试一种新的计量剂量 使用二氧化碳作为推进剂的吸入器。 建议的商业应用： 1.这项无害臭氧的技术可取代现有的计量吸入器推进剂。 2.雾化吸入抗生素可能会减少肺炎的死亡。 3.这种吸入器可能会被证明比针头注射胰岛素更好。 4.这是一种良好的表面活性物质释放系统，可减少急性肺损伤。 5.这可能会提供不能通过任何其他方法给药的药物。

DESCRIPTION (Adapted from the Investigator's Abstract): The chlorofluorocarbon (CFC) propellants currently being used in metered dose inhalers for pulmonary drug delivery are being phased out due to their high ozone depletion potential. An international pharmaceutical industry consortium has proposed that the zero-ozone depletion potential hydrofluoroalkane (HFA) propellants will replace CFCs in metered dose inhalers. There remain, however, crucial reasons to find other drug aerosolization alternatives. Potential problems with the HFA propellants include toxicity, incompatibility with devices, incompatibility with FDA approved inhaler surfactants and reduced bioavailability of some drugs. The investigators have patented a method for the pulmonary aerosol delivery of pharmaceuticals using supercritical fluid carbon dioxide as an inhaler propellant, and have demonstrated its potential usefulness in vivo in several laboratory studies. The investigators have designed a number of inhaler prototypes that use carbon dioxide as a propellant and are seeking funding for additional research and development of these devices. This technology has several advantages including zero-ozone depletion potential propellant, low toxicity of carbon dioxide, and the ability to administer to the lungs lipophilic drugs which cannot currently be delivered by any other method. The investigators propose to improve and thoroughly test a new form of metered dose inhaler which uses carbon dioxide as a propellant. PROPOSED COMMERCIAL APPLICATION: 1. This ozone-friendly technology may replace existing MDI propellants. 2. Aerosol delivery of antibiotics may reduce death from pneumonia. 3. This inhaler may prove to be better than needle injection of insulin. 4. This is an excellent surfactant delivery system to reduce acute lung injury. 5. This may deliver drugs that cannot be administered by any other method.